Related stories
Jazz Pharmaceuticals Raises 2026 Revenue Outlook to $4.775B-$4.85B
The company reported third-quarter Xywav sales up 12% year over year and Zepzelca sales up 32%, partly offset by declines in Epidiolex and Xyrem. Gross-margin guidance remains 89%
M impact | EARNINGS | Nov 09, 2026, 06:02 PM UTC
doValue Q3 Adjusted EBITDA Reaches €65 Million
M impact | EARNINGS | Nov 09, 2026, 05:53 PM UTC
Ferguson Raises Full-Year Sales Guidance; Shares Gain 13%
Ferguson Enterprises raised its full-year sales guidance, with FloWorks acquisition helping support the outlook. Shares rose 13% to $263.05 midday Monday.
M impact | EARNINGS | Nov 09, 2026, 05:48 PM UTC
Theon Reconfirms FY 2026 Guidance, Raises Medium-Term Outlook
Theon reaffirmed its previously upgraded FY 2026 guidance and revised its medium-term guidance upward in its Q3 and nine-month 2026 trading update.
M impact | EARNINGS | Nov 09, 2026, 05:23 PM UTC
European Stocks Rise Sharply on Monday
European stocks closed sharply higher on Monday, erasing the declines from the two prior sessions as markets reassessed the outlook on AI deployment and infrastructure development.
H impact | EARNINGS | Nov 09, 2026, 04:58 PM UTC
Acinque Reports EBITDA of €77.5 Million
M impact | EARNINGS | Nov 09, 2026, 04:50 PM UTC